Acomplia Pricing Likely To Follow Statin Model, Sanofi Says

Sanofi is considering a range of pricing options for the weight-loss/smoking cessation agent, company says; price will ultimately depend on labeling. Statin model would be appropriate if Sanofi can position the drug as long-term therapy to reduce adverse health outcomes.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet